{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T07:37:00Z","timestamp":1779003420911,"version":"3.51.4"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Atopic dermatitis (AD) is a chronic inflammatory skin disease for which many new insights have been gained in recent years through a better understanding of pathophysiology, concomitant diseases and therapeutics in particular. In this review, new and practice\u2010relevant results from current research are presented. Many studies have been performed on the diagnosis of AD and on different subtypes, yet no diagnostic biomarker or clinical predictor of treatment response has been established. For topical treatment, some agents such as Janus kinase (JAK) inhibitors are in advanced stages of clinical trials or already approved in some countries, which will be available in Europe for the treatment of certain eczema subtypes in the foreseeable future. Current systemic therapies in Europe include two antibodies for inhibition of the interleukin (IL)\u20104\/13 signaling cascades and three oral JAK inhibitors with somewhat different efficacy and safety profiles. Among the antibody therapies for AD already advanced in development, promising new targets include blockade of IL\u201031, of neurokinin\u20101 receptor on sensory neurons, and inhibition of the OX40\/OX40L axis for cutaneous dendritic cell and T lymphocyte interaction. Primary prevention and modulation of sequential disease progression as well as effects on concomitant diseases by early therapeutic intervention will be important questions in future research on AD.<\/jats:p>","DOI":"10.1111\/ddg.15050","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T10:42:45Z","timestamp":1679654565000},"page":"349-353","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Atopic dermatitis \u2013 Perspectives and unmet medical needs"],"prefix":"10.1111","volume":"21","author":[{"given":"Timo","family":"Buhl","sequence":"first","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Medical Center G\u00f6ttingen  G\u00f6ttingen Germany"},{"name":"Lower Saxony Institute of Occupational Dermatology University of G\u00f6ttingen  G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Werfel","sequence":"additional","affiliation":[{"name":"Division of Immunodermatology and Allergy Research Department of Dermatology and Allergy Hannover Medical School  Hannover Germany"},{"name":"Lower Saxony Institute of Occupational Dermatology Hannover Medical School  Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.8.3.163"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.106"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13765"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.04.001"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14318"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/ddg.14678","article-title":"Characterization of the effects on pruritus by novel treatments for atopic dermatitis","volume":"20","author":"Bonnekoh H","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14709_g"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.02.001"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15108"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.02.044"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.10.060"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-2217"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09743.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-020-02164-0"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00610-x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ddg.14668","article-title":"JAK\u2010inhibitors in dermatology \u2013 small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects","volume":"20","author":"Klein B","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.696784"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.10.048"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.09.028"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.09.024"},{"key":"e_1_2_8_23_1","first-page":"1435","article-title":"Tralokinumab in atopic dermatitis","volume":"19","author":"Wollenberg A","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/ddg.14371","article-title":"Update \u201cSystemic treatment of atopic dermatitis\u201d of the S2k\u2010guideline on atopic dermatitis","volume":"19","author":"Werfel T","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01199-0"},{"key":"e_1_2_8_27_1","first-page":"1485","article-title":"Pharmacology of inhibitors of Janus kinases \u2013 Part 1: Pharmacokinetics","volume":"20","author":"Eichner A","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_28_1","first-page":"1621","article-title":"Pharmacology of inhibitors of Janus kinases \u2013 Part 2: Pharmacodynamics","volume":"20","author":"Eichner A","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_29_1","unstructured":"Available from:https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RV_STP\/g\u2010l\/januskinase.html. [Last accessed January 22 2023]."},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/ddg.14815","article-title":"Everything is connected in atopic dermatitis","volume":"20","author":"Buhl T","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20873"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0299-4"},{"key":"e_1_2_8_33_1","article-title":"Atopic dermatitis: background, objectives and future perspectives (superresponders)","volume":"12","author":"Ruiz\u2010Villaverde R","year":"2022","journal-title":"Life (Basel)"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.01.001"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.03.010"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00266-6"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.15050","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.15050","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.15050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T11:16:53Z","timestamp":1692703013000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.15050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1111\/ddg.15050"],"URL":"https:\/\/doi.org\/10.1111\/ddg.15050","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]},"assertion":[{"value":"2023-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}